 Diabetes Care. 2013;36(5):1384–95. 23. Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol. 2009;68(6):898–905. 24. Davidson JA, Brett J, Falahati A, Scott D. Mild renal impairment and the efﬁcacy and safety of liraglutide. Endocr Pract. 2011;17(3):345–55. 25. Loghin C, de la Pen ˜a A, Cui X, Zhang X, Geiser JS, Chien JY. Pharmacokinetics of once weekly dulaglutide in special popula- tions [abstract no. 857]. Diabetologia. 2014;57(Suppl 1):S349. 26. Young MA, Wald JA, Matthews JE, Yang F, Reinhardt RR. Effect of renal impairment on the pharmacokinetics, efﬁcacy, and safety of albiglutide. Postgrad Med. 2014;126(3):35–46. 27. Hanefeld M, Arteaga JM, Leiter LA, et al. Efﬁcacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment. Diabetes Obes Metab. 2017;19(11):1594–601. 28. Jensen L, Helleberg H, Roffel A, et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci. 2017;104:31–41. 29. Osonoi T, Saito M, Tamasawa A, et al. Effect of hemodialysis on plasma glucose proﬁle and plasma level of liraglutide in patients with type 2 diabetes mellitus and end-stage renal disease: a pilot study. PLoS One. 2014;9(12):e113468. 30. Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. 
 